[Managing an ophthalmic migraine].
Papeix
C
C
Service d'Ophtalmologie, Hôpital Foch, Suresnes.
Guépratte
N
N
Gout
O
O
Lebuisson
D A
DA
D000328:Adult; D000700:Analgesics / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002110:Caffeine / Q000627:therapeutic use; D000075202:Contraindications; D013181:Cortical Spreading Depression; D004876:Ergot Alkaloids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007511:Ischemia / Q000209:etiology; D008875:Middle Aged; D020325:Migraine with Aura / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D008954:Models, Biological; D012146:Rest; D012607:Scotoma / Q000209:etiology; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014794:Visual Fields
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004876:Ergot Alkaloids; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D002110:Caffeine